FTY720: Sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function

American Journal of Transplantation

Volumn 4, Issue 7, 2004, Pages 1019-1025

  Brinkmann, Volker ^a   Cyster, Jason G ^b   Hla, Timothy ^c  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Endothelium; FTY720; Immunosuppression; S1P; S1P receptor; Sphingosine; T cell circulation

Indexed keywords

FINGOLIMOD; IMMUNOMODULATING AGENT; RECEPTOR PROTEIN; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR 1; UNCLASSIFIED DRUG;

AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; BINDING AFFINITY; BLOOD; CIRCULATION; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; ENDOTHELIUM CELL; HISTOCOMPATIBILITY; HUMAN; INFLAMMATION; KIDNEY GRAFT REJECTION; LYMPHOCYTE FUNCTION; LYMPHOID ORGAN; MOLECULAR BIOLOGY; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN TARGETING; SHORT SURVEY; T LYMPHOCYTE ACTIVATION; TRANSPLANTATION; VASCULAR ENDOTHELIUM;

ANIMALS; CELL PROLIFERATION; CLINICAL TRIALS; ENDOTHELIUM, VASCULAR; HEART RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; LYMPHOCYTES; LYSOPHOSPHOLIPIDS; MODELS, BIOLOGICAL; MODELS, CHEMICAL; PHOSPHORYLATION; PROPYLENE GLYCOLS; PROTEIN BINDING; RATS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE; THYMUS GLAND;

EID: 3042743990     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2004.00476.x     Document Type: Short Survey

References (57)

1. Brinkmann V, Pinschewer DD, Feng L, Chen S. FTY720: Altered lymphocyte traffic results in allograft protection. Transplantation 2001; 72: 764-769.
2. Brinkmann V, Lynch KR. FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. Curr Opin Immunol 2002; 14: 569-575.
3. Tedesco-Silva H, Mourad G, Kahan BD et al. FTY720, a novel immunomodulator - efficacy and safety results from the first Phase 2a study in de novo renal transplantation. Transplantation 2004.
4. Adachi K, Kohara T, Nakao N et al. Design, synthesis and structure-activity relationships of 2-substituted 2-amino- 1,3-propanediols: Discovery of a novel immunosuppressant, FTY720. Bioorg Med Chem Lett 1995; 5: 853-856.
5. Chen JK, Lane WS, Schreiber S. The identification of myriocin-binding proteins. Chem Biol 1999; 6: 221-235.
6. Pinschewer DD, Ochsenbein AF, Odermatt B, Brinkmann V, Hengartner H, Zinkernagel RM. FTY720 immunosuppression impairs effector T-cell peripheral homing without affecting induction, expansion, and memory. J Immunol 2000; 164: 5761-5770.
7. Brinkmann V, Pinschewer D, Chiba K, Feng L. FTY720: a novel transplantation drug that modulates lymphocyte traffic rather than activation. Trends Pharmacol Sci 2000; 21: 49-52.
8. Chiba K, Yanagawa Y, Masubuchi Y et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol 1998; 160: 5037-5044.
9. Bai Y, Liu J, Wang Y et al. 1-selectin-dependent lymphoid occupancy is required to induce alloantigen-specific tolerance. J Immunol 2002; 168: 1579-1589.
10. Henning G, Ohl L, Junt T et al. CC Chemokine receptor 7-dependent and -independent pathways for lymphocyte homing: modulation by FTY720. J Exp Med 2001; 194: 1875-1881.
11. Muller G, Reiterer P, Hopken UE, Golfier S, Lipp M. Role of homeostatic chemokine and sphingosine-1-phosphate receptors in the organization of lymphoid tissue. Ann N Y Acad Sci 2003; 987: 107-116.
12. Brinkmann V, Davis MD, Heise CE et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002; 277: 21453-21457.
13. Mandala S, Hajdu R, Bergstrom J et al. Alteration of lymphocyte trafficking by sphingosine 1-phosphate receptor agonists. Science 2002; 296: 346-349.
14. Matloubian M, Lo C, Cinnamon G et al. Lymphocyte egress from thymus and peripheral lymphoid organs is sphingosine 1-phosphate receptor-1 dependent. Nature 2004; 427: 355-360.
15. Kimura T, Sato K, Kuwabara A et al. Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J Biol Chem 2001; 276: 31780-31785.
16. English D, Welch Z, Kovala AT et al. Sphingosine 1-phosphate released from platelets during clotting accounts for the potent endothelial cell chemotactic activity of blood serum and provides a novel link between hemostasis and angiogenesis. FASEB J 2000; 14: 2255-2265.
17. Prieschl EE, Csonga R, Novotny V, Kikuchi GE, Baumruker T. The balance between sphingosine and sphingosine-1-phosphate is decisive for mast-cell activation after Fc epsilon receptor I triggering. J Exp Med 1999; 190: 1-8.
18. Ancellin N, Colmont C, Su J et al. Extracellular export of sphingosine kinase-1 enzyme. Sphingosine 1-phosphate generation and the induction of angiogenic vascular maturation. J Biol Chem 2002; 277: 6667-6675.
19. Hla T, Lee MJ, Ancellin N, Paik JH, Kluk MJ. Lysophospholipids-receptor revelations. Science 2001; 294: 1875-1878.
20. Sanchez T, Estrada-Hernandez T, Paik JH et al. Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J Biol Chem 2003; 278: 47281-47290.
21. Sallusto F, Lanzavecchia A. Understanding dendritic cell and T-lymphocyte traffic through the analysis of chemokine receptor expression. Immunol Rev 2000; 177: 134-140.
22. Yagi H, Kamba R, Chiba K et al. Immunosuppressant FTY720 inhibits thymocyte emigration. Eur J Immunol 2000; 30: 1435-1444.
23. Graeler MH, Goezl EJ. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G protein-coupled receptors. FASEB J 2004 (Epub ahead of print).
24. Liu CH, Thangada S, Lee MJ, Van Brocklyn JR, Spiegel S, Hla T. Ligand-induced trafficking of the sphingosine-1-phosphate receptor EDG-1. Mol Biol Cell 1999; 10: 1179-1190.
25. Yanagawa Y, Sugahara K, Kataoka H, Kawaguchi T, Masubuchi Y, Chiba K. FTY720, a novel immunosuppressant possessing unique mechanisms. II. FTY720 prolongs skin allograft survival by decreasing T-cell infiltration into grafts but not cytokine production in vivo. J Immunol 1998; 160: 5493-5499.
26. Hwang MW, Matsumori A, Furukawa Y et al. FTY720, a new immunosuppressant, promotes long-term graft survival and inhibits the progression of graft coronary artery disease in a murine model of cardiac transplantation. Circulation 1999; 100: 1322-1329.
27. Fu F, Hu S, Deleo J et al. Long-term islet graft survival in STZ and autoimmune induced diabetes models by immunosuppressive and potential insulinotropic agent FTY720. Transplantation 2002; 73: 1425-1430.
28. Yang Z, Chen M, Fialkow LB et al. The immune modulator FTY720 prevents autoimmune diabetes in nonobese diabetic mice. Clin Immunol 2003; 107: 30-35.
29. Fujino M, Funeshima N, Kitazawa Y et al. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther 2003; 305: 70-77.
30. Xie JH, Nomura N, Koprak SL, Quackenbush EJ, Forrest MJ, Rosen H. Sphingosine-1-phosphate receptor agonist impairs the efficiency of the local immune response by altering trafficking of naive and antigen-activated CD4+ T-cells. J Immunol 2003; 170: 3662-3670.
31. Kim YM, Sachs T, Asavaroengchai W, Bronson R, Sykes M. Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720. J Clin Invest 2003; 111: 659-669.
32. Miyamoto T, Matsumori A, Hwang MW, Nishio R, Ito H, Sasayama S. Therapeutic effects of FTY720, a new immunosuppressive agent, in a murine model of acute viral myocarditis. J Am Coll Cardiol 2001; 37: 1713-1718.
33. Schuurman HJ, Menninger K, Audet M et al. Oral efficacy of the new immunomodulator FTY720 in cynomolgus monkey kidney allotransplantation, given alone or in combination with cyclosporine or RAD. Transplantation 2002; 74: 951-960.
34. Masopust D, Vezys V, Marzo AL, Lefrancois L. Preferential localization of effector memory cells in nonlymphoid tissue. Science 2001; 291: 2413-2417.
35. Schluns KS, Lefrancois L. Cytokine control of memory T-cell development and survival. Nat Rev Immunol 2003; 3: 269-279.
36. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401: 708-712.
37. Nikolova Z, Hof A, Baumlin Y, Hof RP. Efficacy of SDZ RAD compared with CsA monotherapy and combined RAD/FTY720 treatment in a murine cardiac allotransplantation model. Transpl Immunol 2001; 9: 43-49.
38. 1 acts within endothelial cells to regulate vascular maturation. Blood 2003; 102: 3665-3667.
39. Lee MJ, Thangada S, Claffey KP et al. Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell 1999; 99: 301-312.
40. Schaphorst KL, Chiang E, Jacobs KN et al. Role of sphingosine-1 phosphate in the enhancement of endothelial barrier integrity by platelet-released products. Am J Physiol Lung Cell Mol Physiol 2003; 285: 258-267.
41. 3: role of HDL-associated lysophospholipids. J Clin Invest 2004; 113: 569-581.
42. Dudek SM, Garcia JG. Cytoskeletal regulation of pulmonary vascular permeability. J Appl Physiol 2001; 91: 1487-1500.
43. Bassenge E. Endothelial function in different organs. Prog Cardiovasc Dis 1996; 39: 209-228.
44. Labarrere CA, Nelson DR, Park JW. Pathologic markers of allograft arteriopathy: insight into the pathophysiology of cardiac allograft chronic rejection. Curr Opin Cardiol 2001; 16: 110-117.
45. Cooper D, Stokes KY, Tailor A, Granger DN. Oxidative stress promotes blood cell-endothelial cell interactions in the microcirculation. Cardiovasc Toxicol 2002; 2: 165-180.
46. Nikolova Z, Hof A, Rudin M, Baumlin Y, Kraus G, Hof RP. Prevention of graft vessel disease by combined FTY720 and Cyclosporin A treatment in the DA to Lewis rat carotid artery transplantation model. Transplantation 2000; 69: 2525-2530.
47. Anselmo DM, Amersi FF, Shen XD et al. FTY720 pretreatment reduces warm hepatic ischemia reperfusion injury through inhibition of T-lymphocyte infiltration. Am J Transplant 2002; 2: 843-849.
48. Dantas AP, Igarashi J, Michel T. Sphingosine 1-phosphate and control of vascular tone. Am J Physiol Heart Circ Physiol 2003; 284: 2045-2052.
49. Forrest M, Sun SY, Hajdu R et al. Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor sub-types. J Pharmacol Exp Ther 2004 (Epub ahead of print).
50. 3 respectively regulate lymphocyte recirculation and heart rate. J Biol Chem 2004 (Epub ahead of print).
51. Mazurais D, Robert P, Gout B, Berrebi-Bertrand I, Laville MP, Calmels T. Cell type-specific localization of human cardiac S1P receptors. J Histochem Cytochem 2002; 50: 661-670.
52. Liliom K, Sun G, Bunemann M et al. Sphingosylphosphocholine is a naturally occurring lipid mediator in blood plasma: a possible role in regulating cardiac function via sphingolipid receptors. Biochem J 2001; 355: 189-197.
53. Guo J, MacDonell KL, Giles WR. Effects of sphingosine 1-phosphate on pacemaker activity in rabbit sino-atrial node cells. Pflugers Arch 1999; 438: 642-648.
54. Bunemann M, Brandts Bzu Heringdorf DM, van Koppen CJ, Jakobs KH, Pott L. Activation of muscarinic K+ current in guinea-pig atrial myocytes by sphingosine-1-phosphate. J Physiol 1995; 489: 701-777.
55. Yamada M. The role of muscarinic K(+) channels in the negative chronotropic effect of a muscarinic agonist. J Pharmacol Exp Ther 2002; 300: 681-687.
56. Jan LY, Jan YN. Heartfelt crosstalk: desensitization of the GIRK current. Nat Cell Biol 2000; 2: 165-167.
57. Tawadrous MN, Mabuchi A, Zimmermann A, Wheatley AM. Effects of immunosuppressant FTY720 on renal and hepatic hemodynamics in the rat. Transplantation 2002; 74: 602-610.